The goal of the study was to investigate the expression of PD-L1 and pS6 in CTCs isolated from NSCLC patients treated with Osimertinib at baseline, after the first cycle of treatment, and at EOT. The gene discussed is CD274; the disease is non-small cell lung carcinoma.